2026年3月最新《新锐期刊分区表》数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
体验更多LetPub AI科研工具 >> | |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Therapeutic Advances in Hematology THER ADV HEMATOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 5.9
51人评分
我要评分
声誉 7.5 影响力 4.5 速度 6.9 | |||||||||||||||||||||
| 期刊ISSN | 2040-6207 | 安装APP，查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 2040-6215 | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 3.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日：2.71 | |||||||||||||||||||||
| 2024-2025自引率 | 3.2%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 3.5 | |||||||||||||||||||||
| JCI期刊引文指标 | 0.61 | |||||||||||||||||||||
| h-index | 暂无h-index数据 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://uk.sagepub.com/en-gb/chi/journal/therapeutic-advances-hematology | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://mc.manuscriptcentral.com/tah | |||||||||||||||||||||
| 作者指南网址 | https://www.sagepub.com/docs/default-source/msg/submission-guidelines_-Therapeutic-Advances-in-Hematology_-sage-journals.pdf | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis Author: Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C.; Heinloth, Alexandra; Hasabou, Nahla Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419953 Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial Author: Yang, Linyu; Tan, Ke; Liang, Rui; Zhang, Wei; Wang, Yiqun; Chen, Lijuan Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261424845 The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphoma Author: Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251410405 Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation Author: Huang, Xianbo; Wu, Xianhui; Wang, Shasha; Xu, Yu; Mei, Chen; Du, Fengwei; Ren, Yanling; Jin, Jie; Tong, Hongyan; Qian, Jiejing Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417496 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Therapeutic Advances in Hematology的语言要求，还能让Therapeutic Advances in Hematology编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Therapeutic Advances in Hematology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ USD2650; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：blood disorders、blood diseases、haematology 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP | |||||||||||||||||||||
| 出版商 | SAGE PUBLICATIONS LTD | |||||||||||||||||||||
| 涉及的研究方向 | HEMATOLOGY- | |||||||||||||||||||||
| 出版国家或地区 | United States | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 61点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 98.82% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 73.77% | |||||||||||||||||||||
| WOS期刊JCR分区 （ 2024-2025年最新版） | WOS分区等级：2区
| |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版：不在预警名单中 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 《新锐期刊分区表》 （ 2026年3月发布） | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 （ 2025年3月升级版） |
| |||||||||||||||||||||
| 期刊分区表 （ 2023年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2040-6207%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 7 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ USD2650; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Therapeutic Advances in Hematology顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysis Author: Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C.; Heinloth, Alexandra; Hasabou, Nahla Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419953 PubMed DOI |
| 2. | Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial Author: Yang, Linyu; Tan, Ke; Liang, Rui; Zhang, Wei; Wang, Yiqun; Chen, Lijuan Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261424845 PubMed DOI |
| 3. | The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphoma Author: Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251410405 PubMed DOI |
| 4. | Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentation Author: Huang, Xianbo; Wu, Xianhui; Wang, Shasha; Xu, Yu; Mei, Chen; Du, Fengwei; Ren, Yanling; Jin, Jie; Tong, Hongyan; Qian, Jiejing Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417496 PubMed DOI |
| 5. | Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review Author: You, Jiawen; Zhang, Yuanyuan; Meng, Yuan; Zhao, Yiming; Huang, Huiqing; Chen, Wendong; Meng, Jianbo Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417132 PubMed DOI |
| 6. | Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therapy Author: Al-Sanabra, Ola M.; Abbas, Manal A.; Haza, Wafa J.; Hazaa, Abeer A Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417140 PubMed DOI |
| 7. | Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trial Author: Huang, Qiulin; Liu, Rongrong; Zheng, Baoshi; Liu, Lianjin; Xiao, Hongwen; Wu, Meiqing; Shi, Lingling; Yang, Gaohui; Wei, Zhenbin; Zhou, Qi; Chen, Yinghua; Liu, Yanye; Fan, Jing; Zhou, Xuemei; Li, Ruolin; Zeng, Zhiyu; Zhang, Zhongming; Lai, Yongrong Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261416816 PubMed DOI |
| 8. | Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application Author: Hua, Zhengjie; Miao, Wenjuan; Zhang, Ping; Yang, Renchi Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419941 PubMed DOI |
| 9. | The efficacy and safety of asciminib treatment in patients with chronic myeloid leukemia as a second-line or beyond second-line treatment: a systematic review and meta-analysis Author: Fan, Zixin; Xie, Jiayi; Su, Pinying; Tai, Jingye; Feng, Weiyi; Xu, Rui; Ouyang, Yun Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2025; Vol. 16, Issue , pp. -. DOI: 10.1177/20406207251342203 PubMed DOI |
| 10. | Epstein-Barr virus reactivation after haplo-peripheral blood stem cell transplantation in patients with hematological malignancies: immune reconstitution and influence on survival Author: Ma, Ling; Zhang, Ying; Wang, Ting; Cai, Yu; Yang, Jun; Tong, Yin; Huang, Chongmei; Qiu, Huiying; Zhou, Kun; Xu, Xiaowei; Niu, Jiahua; Shen, Chang; Xia, Xinxin; Wei, Yu; Shao, Jie; Yang, Min; Cao, Jingjing; Song, Xianmin; Wan, Liping Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2025; Vol. 16, Issue , pp. -. DOI: 10.1177/20406207251335477 PubMed DOI |
|
|
  | ||||||||||||||||
|
投稿状态统计： 我要评分： | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范？试试稿件自查工具，一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验：共0条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
投稿信 (Cover Letter) 模板
